MEGA GENOMICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.59 HKD | +0.21% |
|
+3.23% | -6.89% |
| 03-26 | Mega Genomics Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-12 | Mega Genomics Stockholders to Vote March 1 on Continuing Transactions | MT |
Valuation
| Fiscal Period: December | 2022 |
|---|---|
| Capitalization 1 | 2,747 |
| Enterprise Value (EV) 1 | 2,349 |
| P/E ratio | -128 x |
| Yield | - |
| Capitalization / Revenue | 18.8 x |
| EV / Revenue | 16.1 x |
| EV / EBITDA | -146 x |
| EV / FCF | 103,414,764 x |
| FCF Yield | 0% |
| Price to Book | 4.44 x |
| Nbr of stocks (in thousands) | 239,234 |
| Reference price 2 | 11.48 |
| Announcement Date | 23-04-27 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net sales 1 | 123.7 | 203.2 | 237.2 | 145.7 |
| EBITDA 1 | 51.93 | 116.3 | 117 | -16.08 |
| EBIT 1 | 43.35 | 107.8 | 108.7 | -24.4 |
| Operating Margin | 35.05% | 53.03% | 45.83% | -16.75% |
| Earnings before Tax (EBT) 1 | 38.29 | 94.9 | 95.88 | -21.42 |
| Net income 1 | 29.69 | 79.1 | 79.02 | -17.62 |
| Net margin | 24% | 38.92% | 33.31% | -12.09% |
| EPS | - | - | 0.6209 | -0.0900 |
| Free Cash Flow | - | 260 | -193.5 | 22.72 |
| FCF margin | - | 127.94% | -81.58% | 15.59% |
| FCF Conversion (EBITDA) | - | 223.55% | - | - |
| FCF Conversion (Net income) | - | 328.71% | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 22-06-09 | 22-06-09 | 22-06-09 | 23-04-27 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 28.5 | 191 | 451 | 398 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | 260 | -194 | 22.7 |
| ROE (net income / shareholders' equity) | - | 91.1% | 18.1% | -2.68% |
| ROA (Net income/ Total Assets) | - | 18.8% | 11.1% | -2.06% |
| Assets 1 | - | 421.2 | 712.9 | 853.5 |
| Book Value Per Share | - | - | 3.470 | 2.580 |
| Cash Flow per Share | - | - | 1.200 | 1.670 |
| Capex 1 | 0.58 | 1.05 | 4.16 | 5.01 |
| Capex / Sales | 0.47% | 0.51% | 1.75% | 3.44% |
| Announcement Date | 22-06-09 | 22-06-09 | 22-06-09 | 23-04-27 |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.89% | 291M | |
| -16.80% | 8.79B | |
| +65.33% | 4.19B | |
| -4.03% | 2.48B | |
| -42.54% | 2.29B | |
| -6.61% | 1.97B | |
| -20.29% | 1.56B | |
| -41.24% | 1.22B | |
| +10.26% | 1.13B | |
| +18.74% | 933M |
- Stock Market
- Equities
- 6667 Stock
- Financials Mega Genomics Limited
